tyrosyl-alanyl-glycyl-phenylalanyl-leucyl-arginine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tyrosyl-alanyl-glycyl-phenylalanyl-leucyl-arginine
• 英文别名: (D-Ala2)-leucine enkephalin-arg；2-[[2-[[2-[[2-[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoylamino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
• 化学式: C₃₅H₅₁N₉O₈
• 分子量: 725.845
• InChiKey: GDPHPXYFLPDZGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  52
• 可旋转键数：
  21
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  293
• 氢给体数：
  10
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  carbobenzoxy-o-benzyl-tyrosyl-alanyl-glycyl-phenylalanyl-leucyl-arginine 、 苯甲醚 在 钯 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 生成 tyrosyl-alanyl-glycyl-phenylalanyl-leucyl-arginine
  参考文献：
  名称：

  US4695622

  摘要：

  公开号：

文献信息

• Antiviral Immunotropic Agent for the Treatment of Acute Respiratory Viral Infections
  申请人：PVP LABS PTE. LTD.

  公开号：US20190322701A1

  公开（公告）日：2019-10-24

  The proposed methods of treatment pertain to medicine, in particular pharmacology, and concerns the application of a nasal medicinal composition containing hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine or its pharmaceutically acceptable salt for the treatment of acute respiratory viral infections (ARVIs), in particular those caused by the influenza virus.

  提议的治疗方法涉及医学，特别是药理学，涉及应用含有六肽基酪氨酸-D-丙氨酰-甘氨酰-苯丙氨酰-亮氨酰-精氨酸或其药学上可接受的盐的鼻用药物组合物，用于治疗急性呼吸道病毒感染（ARVIs），特别是由流感病毒引起的感染。
• HEXAPEPTID
  申请人：VSESOJUZNY KARDIOLOGICHESKY NAUCHNY TSENTR AKADEMII MEDITSINSKIKH NAUK SSSR

  公开号：EP0189485A1

  公开（公告）日：1986-08-06

  Hexapeptide having a Tyr-Ala-Gly-Phe-Leu-Arg structure and possessing antipancreanecrotic activity.

  具有 Tyr-Ala-Gly-Phe-Leu-Arg 结构的六肽，具有抗盘旋硬化活性。
• ANTIVIRAL IMMUNOTROPIC AGENT FOR THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS
  申请人：PVP Labs PTE. Ltd.

  公开号：EP3556377A1

  公开（公告）日：2019-10-23

  The proposed methods of treatment pertain to medicine, in particular pharmacology, and concerns the application of a nasal medicinal composition containing hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine or its pharmaceutically acceptable salt for the treatment of acute respiratory viral infections (ARVIs), in particular those caused by the influenza virus.

  建议的治疗方法涉及医学，特别是药理学，涉及一种含有六肽酪氨酰-D-丙氨酰-甘氨酰-苯丙氨酰-亮氨酰-精氨酸或其药学上可接受的盐的鼻腔药物组合物，用于治疗急性呼吸道病毒感染（ARVI），特别是由流感病毒引起的感染。
• AGENT FOR THE TREATMENT OF SKIN WOUNDS OR BURNS
  申请人：PVP Labs PTE. Ltd.

  公开号：EP3622964A1

  公开（公告）日：2020-03-18

  The invention pertains to medicine and concerns the application of the hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine in the treatment of skin wounds or burns as a medicinal product for topical use. Agent for the treatment of skin wounds of burns in the form of a dosage form for topical use containing the hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine at 0.02 - 0.5 weight % as the active ingredient, with a pharmaceutically acceptable excipient / pharmaceutically acceptable excipients making up the rest. The agent contributes to rapid healing of skin wounds and burns by stimulating tissue regeneration processes in the affected area and reducing the severity of productive inflammation. 2 dependent claims, 5 examples, 4 tables and 4 figures.

  本发明涉及医药领域，涉及六肽酪氨酰-D-丙氨酰-甘氨酰-苯丙氨酰-亮氨酰-精氨酸作为外用药剂在治疗皮肤创伤或烧伤中的应用。 用于治疗皮肤创伤或烧伤的外用制剂，其剂型含有 0.02 - 0.5 重量百分比的六肽酪氨酰-D-丙氨酰-甘氨酰-苯丙氨酰-亮氨酰-精氨酸作为活性成分，其余为药学上可接受的辅料/药学上可接受的赋形剂。 该制剂通过刺激受影响区域的组织再生过程和减轻生产性炎症的严重程度，有助于皮肤伤口和烧伤的快速愈合。2 项从属权利要求，5 个实例，4 个表格和 4 张图。
• APPLICATION OF DALARGIN FOR THE PREVENTION OF VIRAL RESPIRATORY INFECTIONS AND PREVENTION OF THE DEVELOPMENT OF COMPLICATIONS DURING VIRAL RESPIRATORY INFECTIONS
  申请人：PVP Labs PTE. Ltd.

  公开号：EP3906934A1

  公开（公告）日：2021-11-10

  The invention is related to pharmaceutics and medicine and concerns the application of Dalargin solution in spray form for the irrigation of the oral cavity or nasopharynx in the form of inhalations using a nebulizer for the prevention of VRIs or for the prevention of complications, especially in the early stages of the disease. The invention consists in the application of Dalargin in spray form and/or in an inhaled form for the prevention of VRIs or for the prevention of their complications. The invention expands the technical toolkit of products for inhalation therapy for the prophylaxis of VRIs or prevention of the development of complications.

  本发明与制药和医学有关，涉及使用喷雾器以吸入的形式将达拉金溶液喷洒在口腔或鼻咽部，用于预防VRI或预防并发症，尤其是在疾病的早期阶段。本发明包括以喷雾和/或吸入形式应用达拉金，以预防 VRI 或预防其并发症。本发明扩展了吸入疗法产品的技术工具包，用于预防 VRI 或预防并发症的发生。